Sequencing Therapies in Non-Hodgkin Lymphomas
Journal of the Advanced Practitioner in Oncology · 27.02.2026 · 17 (2)
DOI: 10.6004/jadpro.2026.17.2.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 27.02.2026. Verfasst von F. Brianne Buchanan und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Oncology advanced practitioners treating relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (NHLs) are practicing in a rapidly evolving landscape with options expanding to include BTK inhibitors, bispecific antibodies, and CAR T-cell therapies. At JADPRO Live 2025, speakers discussed sequencing and how mechanistic, safety, financial, logistical, and quality-of-life factors shape decision-making.
Zitieren
APA
Buchanan, F. B., PA-C, Grgic, T., PharmD, BCOP, & CPP (2026). Sequencing Therapies in Non-Hodgkin Lymphomas. Journal of the Advanced Practitioner in Oncology, 17(2). https://doi.org/10.6004/jadpro.2026.17.2.12
Vancouver
Buchanan FB, PA-C, Grgic T, PharmD, BCOP, CPP. Sequencing Therapies in Non-Hodgkin Lymphomas. Journal of the Advanced Practitioner in Oncology. 2026;17(2). doi:10.6004/jadpro.2026.17.2.12
BibTeX
@article{Buchanan2026,
author = {Buchanan, F. Brianne and PA-C and Grgic, Tatjana and PharmD and BCOP and CPP},
title = {Sequencing Therapies in Non-Hodgkin Lymphomas},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {2},
doi = {10.6004/jadpro.2026.17.2.12}
}
EUVIMED